Candel Therapeutics shares rose 19.3% in the premarket due to good mid-term trial data for lung cancer treatment
由于肺癌治疗的中期试验数据良好Candel Therapeutics股价盘前上涨19.3％
Candel Therapeutics shares rose 19.3% in the premarket due to good mid-term trial data for lung cancer treatment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.